Mondego Bio doses first humans with oral MB-388, an immunotherapy-resistance drug targeting the PTPN2/PTPN1 pathway. Phase 1a data expected December 2026.

Cork startup ArrayPatch builds dissolving microneedles entirely from the drug itself — no polymer — and may put GLP-1 obesity ...

A review in Molecular Cancer examines how antibody-drug conjugates treat solid tumors while addressing clinical resistance, ...

A scientific review evaluates how herbal phytochemicals mitigate drug-induced kidney toxicity in preclinical studies while ...

Sionna Therapeutics is rated Hold after SION-719 failed its Phase 2a endpoint in cystic fibrosis when combined with Trikafta.

For pharmacists, physicians, and nurses handling anti-MRSA drugs in the ICU, we have summarized the key points for vancomycin ...

Mouse toxicity findings and insufficient juvenile-toxicity data led the FDA to place Bright Minds Biosciences' (NASDAQ: DRUG) ...

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The ...

Shareholders of Bright Minds Biosciences (NASDAQ: DRUG) are holding losses after the stock sold off when the FDA placed the ...

In preclinical studies, FT2109 showed a differentiated profile, including high potency and oral bioavailability, anti-inflammatory activity comparable to biologic TNF inhibition in preclinical disease ...

Good afternoon, and welcome, everyone, to the RenovoRx Third Quarter 2026 Earnings Results Conference Call. I am joined today ...

Collaboration with Imperial College London and City St George’s, University of London combines £2.1 million in MRC ...